How patent thickets affect biosimilar access & Bristol's CEO on new drug launches

Taking stock of the drug industry, from the lab to the medicine chest  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Patent thickets are thwarting U.S. availability of lower-cost biosimilar medicines, study finds By Ed Silverman Adobe A new analysis underscores concerns that drug makers abuse the patent system when they look to thwart rivals. Read More STAT+: Bristol CEO Giovanni Caforio on new drug launches and acquisitions in 2022 By Adam Feuerstein Emilie Pickering for STAT With six recent drug launches and another three on the way, Bristol expects to offset the lost Revlimid revenue and continue to grow. Read More At Davos, a 'good news, bad news' message emerges about Covid-19 By Ed Silverman Sergio Flores/Getty Images Anthony Fauci, Moderna CEO Stéphane Bancel, and other experts spoke at Davos about Covid-19 vaccine equity and potential future variants. Read More Sponsor content by STAT Events Early Bird Access Extended: The Breakthrough Science Summit For one more week only, access our best rates! On March 31, we’re gathering knowledgeable insiders – from pharma executives to cutting-edge researchers – to hear their takes on the innovations in tech and procedures that are set to change the face of health and medicine. Early bird pricing ends Friday, Jan. 21 so get your pass now! Opinion: Uncorking today's Covid-19 supply chain to meet the challenges of future pandemics By Jeff Fischer Jon Cherry/Getty Images The U.S. needs a more robust domestic supply chain for better — and quicker — access to testing and other medical supplies. Read More Tuesday, January 18, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser